top of page

AbbVie, Bristol-Myers Squibb partner on combo treatment for lung cancer

AbbVie and Bristol-Myers Squibb (BMS) are collaborating on a clinical trial combining both companies’ checkpoint inhibitors to treat relapsed extensive-stage small cell lung cancer (SCLC).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page